Agenda of the COMP meeting 21-23 May 2024
Submitted by Anonymous (not verified) on 21 May 2024 - 8:41
Agenda of the COMP meeting 21-23 May 2024
Have your say and help shape EMA’s future communications
Submitted by Anonymous (not verified) on 21 May 2024 - 8:00
Have your say and help shape EMA’s future communications
European medicines network designated as WHO listed authority
Submitted by Anonymous (not verified) on 20 May 2024 - 13:55
European medicines network designated as WHO listed authority
Minimum inhibitory concentration (MIC) breakpoints
Submitted by Anonymous (not verified) on 17 May 2024 - 15:37
Minimum inhibitory concentration (MIC) breakpoints
On-boarding of users to Substance, Product, Organisation and Referentials (SPOR) data services
Submitted by Anonymous (not verified) on 17 May 2024 - 14:00
On-boarding of users to Substance, Product, Organisation and Referentials (SPOR) data services
Human medicines European public assessment report (EPAR): Onivyde pegylated liposomal (previously known as Onivyde), irinotecan hydrochloride trihydrate, Date of authorisation: 14/10/2016, Revision: 12, Status: Authorised
Submitted by Anonymous (not verified) on 17 May 2024 - 13:54
Human medicines European public assessment report (EPAR): Onivyde pegylated liposomal (previously known as Onivyde), irinotecan hydrochloride trihydrate, Date of authorisation: 14/10/2016, Revision: 12, Status: Authorised
European Medicines Agency’s data protection notice for the EMA Help Desk
Submitted by Anonymous (not verified) on 17 May 2024 - 13:22
European Medicines Agency’s data protection notice for the EMA Help Desk
Products Management Services (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe - Chapter 1
Submitted by Anonymous (not verified) on 17 May 2024 - 13:16
Products Management Services (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe - Chapter 1
Hydroxyprogesterone caproate medicines to be suspended from the EU market
Submitted by Anonymous (not verified) on 17 May 2024 - 11:30
Hydroxyprogesterone caproate medicines to be suspended from the EU market
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2024
Submitted by Anonymous (not verified) on 17 May 2024 - 11:00
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2024